BioMarin Pharmaceutical I... (BMRN)
NASDAQ: BMRN
· Real-Time Price · USD
61.91
-0.80 (-1.28%)
At close: May 02, 2025, 3:59 PM
62.85
1.51%
After-hours: May 02, 2025, 05:57 PM EDT
-1.28% (1D)
| Bid | 61.75 |
| Market Cap | 11.87B |
| Revenue (ttm) | 2.94B |
| Net Income (ttm) | 523.88M |
| EPS (ttm) | 2.21 |
| PE Ratio (ttm) | 28.02 |
| Forward PE | 15.18 |
| Analyst | Buy |
| Ask | 62.4 |
| Volume | 1,806,418 |
| Avg. Volume (20D) | 1,658,900 |
| Open | 64.72 |
| Previous Close | 62.71 |
| Day's Range | 60.92 - 65.40 |
| 52-Week Range | 52.93 - 94.85 |
| Beta | 0.27 |
About BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 26, 1999
Employees 3,040
Stock Exchange NASDAQ
Ticker Symbol BMRN
Website https://www.biomarin.com
Analyst Forecast
According to 21 analyst ratings, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is $90, which is an increase of 45.36% from the latest price.
Stock ForecastsEarnings Surprise
BioMarin Pharmaceutical has released their quartely earnings
on May 1, 2025:
2 months ago
+4.76%
BioMarin Pharma shares are trading higher after th...
Unlock content with
Pro Subscription
2 months ago
+1.16%
BioMarin Pharma shares are trading higher after the company reported better-than-expected Q4 financial results.
